Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
29 Agosto 2023 - 12:30PM
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to
unraveling the mysteries of the brain to treat neuroscience
diseases, announced that members of the management team will
participate in the Morgan Stanley 21st Annual Global Healthcare
Conference on Tuesday, September 12, 2023. President and chief
executive officer Ron Renaud will participate in a fireside chat at
9:30 AM ET.
The live webcast of the fireside chat can be accessed on the
investor relations section of the Cerevel Therapeutics website
here. A replay will be available in the same section of the
company’s website.
About Cerevel TherapeuticsCerevel Therapeutics
is dedicated to unraveling the mysteries of the brain to treat
neuroscience diseases. The company is tackling diseases by
combining its deep expertise in neurocircuitry with a focus on
targeted receptor subtype selectivity and a differentiated approach
to pharmacology. Cerevel Therapeutics has a diversified pipeline
comprised of five clinical-stage investigational therapies and
several preclinical compounds with the potential to treat a range
of neuroscience diseases, including schizophrenia, Alzheimer’s
disease psychosis, epilepsy, panic disorder, and Parkinson’s
disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is
advancing its current research and development programs while
exploring new modalities through internal research efforts,
external collaborations, or potential acquisitions. For more
information, visit www.cerevel.com.
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements that are based on management’s beliefs and assumptions
and on information currently available to management. In some
cases, you can identify forward-looking statements by the following
words: “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements about:
the potential attributes and benefits of our product candidates;
and our presentation at an upcoming conference. We cannot assure
you that the forward-looking statements in this press release will
prove to be accurate. Furthermore, if the forward-looking
statements prove to be inaccurate, the inaccuracy may be material.
Actual performance and results may differ materially from those
projected or suggested in the forward-looking statements due to
various risks and uncertainties, including, among others: clinical
trial results may not be favorable; uncertainties inherent in the
product development process (including with respect to the timing
of results and whether such results will be predictive of future
results); the impact of COVID-19, the post-COVID environment and
other factors on the timing, progress and results of clinical
trials; our ability to recruit and enroll suitable patients in our
clinical trials, including the effectiveness of mitigation
measures; whether and when, if at all, our product candidates will
receive approval from the FDA or other regulatory authorities, and
for which, if any, indications; competition from other
biotechnology companies; uncertainties regarding intellectual
property protection; and other risks identified in our SEC filings,
including those under the heading “Risk Factors” in our Quarterly
Report on Form 10-Q filed with the SEC on August 2, 2023 and our
subsequent SEC filings. In light of the significant uncertainties
in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other
person that we will achieve our objectives and plans in any
specified time frame, or at all. The forward-looking statements in
this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Media Contact:
Anna Robinson
Cerevel Therapeutics
anna.robinson@cerevel.com
Investor Contact:
Matthew Calistri
Cerevel Therapeutics
matthew.calistri@cerevel.com
Grafico Azioni Cerevel Therapeutics (NASDAQ:CERE)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Cerevel Therapeutics (NASDAQ:CERE)
Storico
Da Giu 2023 a Giu 2024